[CH3:1][CH:2]1[CH2:7][CH:6]([NH2:8])[CH:5]([CH:9]([CH3:11])[CH3:10])[CH2:4][CH2:3]1.[C:12](Cl)(=[O:19])[C:13]1[CH:18]=[CH:17][CH:16]=[CH:15][CH:14]=1>>[CH:9]([C@@H:5]1[CH2:4][CH2:3][C@@H:2]([CH3:1])[CH2:7][C@@H:6]1[NH:8][C:12](=[O:19])[C:13]1[CH:18]=[CH:17][CH:16]=[CH:15][CH:14]=1)([CH3:11])[CH3:10].[CH:9]([C@H:5]1[CH2:4][CH2:3][C@H:2]([CH3:1])[CH2:7][C@H:6]1[NH:8][C:12](=[O:19])[C:13]1[CH:18]=[CH:17][CH:16]=[CH:15][CH:14]=1)([CH3:11])[CH3:10]The aforementioned product is obtained as a colorless solid containing in total 97.6% of the desired neomenthylamine derivatives from racemic neomenthylamine, as in the GP, by reaction with benzoylchloride. Furthermore, two further isomeric menthylamine derivatives are present at 1.3% and 1.0%, corresponding to a purity of isomeric N-(-2-isopropyl-5-methylcyclohexyl)benzamides of 99.9%.
Loading…